Loading
A phase 2 trial of Abiraterone acetate, Apalutamide, Enzalutamide in metastatic cancer and prostate cancer, run by Sun Pharmaceutical Industries Limited, now recruiting.
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. is a phase 2 interventional study registered as NCT05422911 by Sun Pharmaceutical Industries Limited, with 192 participants planned, started 2022-08-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abiraterone acetate, Apalutamide, Enzalutamide. Conditions listed: Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/